ISR [Bioanalytics]

posted by The Outlaw Torn – Europe, 2012-11-29 16:58 (4563 d 06:29 ago) – Posting: # 9636
Views: 10,772

Dear all,

I heard from a little birdie that the CMDh is looking into the whole incurred sample re-analysis fiasco. Has anyone heard anything new about it?

Also, I don't beleive this was discussed previously, but here's the situation. We have a client who wishes to run a repeat use procedure. As the BE studies for the original procedure are no longer compliant with the new guideline regarding ISR, they are concerned that if they run this repeat use procedure their original MA might be in danger of being revoked because the BE studies in the original precedure are no longer compliant with the current guidelines (ie. they might have to withdraw the product). This makes absolutely no sense to me. To withdraw a product that has already been on the market for a length of time, wouldn't the authorities need some kind of safety concern to do this?

BTW, has anyone heard anything new about the new Modified-release guideling?

Thank you all.

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,675 registered users;
65 visitors (0 registered, 65 guests [including 10 identified bots]).
Forum time: 00:28 CEST (Europe/Vienna)

Every man gets a narrower and narrower field of knowledge
in which he must be an expert in order to compete with other people.
The specialist knows more and more about less and less
and finally knows everything about nothing.    Konrad Lorenz

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5